Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing cancer therapies. Its lead programs include Revuforj (revumenib), a menin inhibitor being developed for relapsed or refractory acute leukemia, and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody for chronic graft-versus-host disease. The company is also advancing revumenib in additional settings, including relapsed or refractory acute myeloid leukemia with an NPM1 mutation, in combination regimens for NPM1-mutant AML or KMT2A-rearranged acute leukemia, and metastatic colorectal cancer. Other development programs include axatilimab for idiopathic pulmonary fibrosis and Entinostat, a Class 1 HDAC inhibitor. Syndax has a licensing, development, and commercialization agreement with Eddingpharm International Company Limited for Entinostat. Founded in 2005, the company is headquartered in New York, New York.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-SNDX
|
$25.33
|
13.0% Upside
|
Fair
|
$39
|
74.0% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
-8.1x
|
47.3x
|
9.1x
|
1.975 B
|
1.951 B
|
14.9%
|
89.8%
|
-2.0
|
—
|
114.4%
|
